Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer; Nizar M. Tannir; David F. McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K. Choueiri; Elizabeth R. Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Hans J. Hammers; Bernard Escudier

doi:https://doi.org/10.1056/nejmoa1712126

doi.org/10.1056/nejmoa1712126

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

,

,

..., Bernard Escudier

97

Volume: 378, Issue: 14, Pages: 1277 - 1290

Published: Apr 5, 2018

Abstract

Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell...

Paper Fields

Paper Details

Title

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

DOI

doi.org/10.1056/nejmoa1712126

Published Date

Apr 5, 2018

Volume

378

Issue

14

Pages

1277 - 1290

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History